SPDR® S&P Biotech ETF (XBI)

Delayed Data
As of Jan 17
 -0.81 / -0.83%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

These 3 Biotech Stocks Could Be Top Stocks in 2020
Jan 11 / MotleyFool.com - Paid Partner Content
Better Buy: Biogen vs. Gilead Sciences
Jan 11 / MotleyFool.com - Paid Partner Content


1 month-0.38% 3 years+15.10%
3 months+20.73% 5 years+8.11%
1 year+16.59% Since inception+13.82%
Data through 01/18/2020

Quote Details

Previous close$97.08
Open day’s range95.84 – 97.64
Net asset value (NAV)96.20 (01/17/2020)
Daily volume5,673,159
Average volume (3 months)5,037,279
Data as of 8:00pm ET, 01/17/2020

Peer Comparisonvs. Health ETFs

Performance 5-yr return+8.11%+8.75%
Expense Gross exp ratio0.35%1.25%
Risk 5 year sharpe ratio0.410.52
Net assets$4.3B$3.2B
Average market cap$4.2B$43.9B
Average P/E--27.7
Dividend / Share--0.30%


VHT Vanguard Health Care Index Fund ETF Shar...
FHLC Fidelity MSCI Health Care Index ETF
IXJ iShares Global Healthcare ETF


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
MRTX Mirati Therapeutics Inc1.92%
EXAS Exact Sciences Corp1.78%
BMRN Biomarin Pharmaceutical Inc1.77%
ICPT Intercept Pharmaceuticals Inc1.74%
GBT Global Blood Therapeutics Inc1.73%
-- 1.72%
AMGN Amgen1.71%
ABBV AbbVie1.69%
SGEN Seattle Genetics Inc1.68%
VRTX Vertex Pharmaceuticals Inc1.68%